Prasurel 10 mg (Tablet)
Unit Price: ৳ 20.00 (2 x 10: ৳ 400.00)
Strip Price: ৳ 200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Prasugrel hydrochloride |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Reduces rate of thrombotic cardiovascular events
- Indicated for acute coronary syndrome
- Management with percutaneous coronary intervention
- For unstable angina or non-ST-elevation myocardial infarction (NSTEMI)
- For ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI
Pharmacology
- Inhibitor of platelet activation and aggregation
- Irreversible binding to P2Y12 class of ADP receptors on platelets
Dosage & Administration
- Initiated with a single 60 mg oral loading dose
- Continued at 10 mg once daily with or without food
- Consider 5 mg once daily for patients <60 kg
- Should be taken with aspirin (75 mg to 325 mg) daily
Interaction
- Increases risk of bleeding when coadministered with warfarin
- May increase bleeding risk when coadministered with NSAIDs
- Compatible with drugs that are inducers or inhibitors of cytochrome P450 enzymes
- Can be administered with aspirin, heparin, GPIIb/IIIa inhibitors, statins, and drugs that elevate gastric pH
Contraindications
- Active pathological bleeding such as peptic ulcer or intracranial haemorrhage
- History of prior transient ischemic attack or stroke
Side Effects
- Bleeding
- Thrombotic thrombocytopenic purpura
- Other side effects include headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash, etc.
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Reproductive and developmental toxicology studies in rats and rabbits
- Unknown excretion in human milk
- Should be used during nursing only if potential benefit justifies potential risk
Precautions & Warnings
- Risk increases in patients receiving Prasurel who undergo CABG
- Premature discontinuation increases risk of stent thrombosis, MI, and death
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- Increased risk of fatal bleeding events in patients over 75 years of age
- No dosage adjustment necessary for patients with renal impairment
- Limited experience in patients with end-stage renal disease
- No dosage adjustment needed in patients with mild to moderate hepatic impairment
Overdose Effects
- Lethality observed in rats after administration of 2000 mg/kg
- Platelet transfusion may restore clotting ability
- Active metabolite not likely to be removed by dialysis
Therapeutic Class
- Anti-platelet drugs
Storage Conditions
- Keep in dry place and away from light and heat
- Keep out of the reach of children